<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858776</url>
  </required_header>
  <id_info>
    <org_study_id>CIP0218</org_study_id>
    <nct_id>NCT04858776</nct_id>
  </id_info>
  <brief_title>Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT</brief_title>
  <acronym>DEXTERITY-SCI</acronym>
  <official_title>Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT (DEXTERITY-SCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercator MedSystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercator MedSystems, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of a medical procedure that utilizes a commercially available catheter (the&#xD;
      Bullfrog® Micro-Infusion Device) to locally deliver a commercially available&#xD;
      anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after&#xD;
      DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60&#xD;
      days prior to recanalization. The goal of the study is to see if local anti-inflammation&#xD;
      helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24&#xD;
      months after the initial DVT recanalization procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically relevant primary patency</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from loss of patency with associated symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from major adverse event (MAE)</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from composite of all-cause death, clinically significant pulmonary embolism, major bleeding, target vessel thrombosis, infection of treatment or insertion site, or AV fistula of treatment site</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Iliofemoral; Thrombosis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Perivascular dexamethasone</intervention_name>
    <description>Dexamethasone delivery around target vein segment(s)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Perivascular sham</intervention_name>
    <description>Saline delivery around target vein segment(s)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form prior to receiving any&#xD;
             non-standard of care, protocol-specific procedures.&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures including completion of&#xD;
             questionnaires and follow-up visits and availability for the duration of the study.&#xD;
&#xD;
          3. Male or female, aged 18 to 89 years.&#xD;
&#xD;
          4. For females of reproductive potential: negative pregnancy test ≤7 days before the&#xD;
             procedure, use of highly effective contraception for at least 1 month prior to&#xD;
             screening, and agreement to use such a method during study participation.&#xD;
&#xD;
          5. Negative COVID-19 test result within 5 days prior to procedure or evidence of COVID-19&#xD;
             vaccine or booster within past 12 months.&#xD;
&#xD;
          6. Onset of DVT symptoms 14 to 60 days prior to intervention in the study limb with need&#xD;
             for stenting of the iliofemoral segment.&#xD;
&#xD;
          7. Ability to take oral medication and be willing to adhere to the prescribed&#xD;
             anti-coagulant regimen.&#xD;
&#xD;
          8. Prescription for at least 14 days low molecular weight heparin followed by therapeutic&#xD;
             anticoagulant of investigator's choice for 12-month minimum as part of&#xD;
             post-interventional medication regimen.&#xD;
&#xD;
          9. Minimum of 30 days of prescribed antiplatelet agent (aspirin or P2Y12 inhibitor).&#xD;
&#xD;
         10. Hemodynamically significant DVT (&gt;50% area obstruction) spanning at least (a) the&#xD;
             iliofemoral and common femoral veins or (b) the common femoral vein with extension&#xD;
             into the femoral vein and/or profunda vein. Extent of thrombus in the popliteal and&#xD;
             calf veins is allowed.&#xD;
&#xD;
         11. Successful recanalization of the target vein with at least one patent inflow vein&#xD;
             (femoral or profunda).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current enrollment in another non-registry clinical study of systemic drug therapy or&#xD;
             another device study that has not completed its primary endpoint, including prior&#xD;
             enrollment in this study. Concurrent enrollment in registry studies of approved&#xD;
             devices or drugs are acceptable.&#xD;
&#xD;
          2. Lack of capability of understanding the nature, significance and implications of the&#xD;
             clinical trial.&#xD;
&#xD;
          3. Body Mass Index &gt; 40 kg/m2.&#xD;
&#xD;
          4. Non-ambulatory status prior to DVT occurrence.&#xD;
&#xD;
          5. In the target vein segment: previously treated symptomatic DVT within the previous 12&#xD;
             months.&#xD;
&#xD;
          6. In the contralateral (non-study) leg: symptomatic DVT that, in the opinion of the&#xD;
             operating physician, will require surgery in the following 30 days.&#xD;
&#xD;
          7. Limb-threatening circulatory compromise with ankle-brachial index &lt;0.4, absolute ankle&#xD;
             pressure &lt;50 mmHg or absolute toe pressure &lt;30 mmHg.&#xD;
&#xD;
          8. Pulmonary embolism (PE) defined as either massive (Systolic blood pressure &lt; 90 mmHg&#xD;
             and/or patient on IV vasoactive medication to support blood pressure), or intermediate&#xD;
             high-risk PE, as defined by the European Society Guideline on management of PE.&#xD;
             Low-risk PE and/or intermediate low-risk PE can be enrolled.&#xD;
&#xD;
          9. Inability to tolerate contemporary venous intervention procedure due to severe dyspnea&#xD;
             or acute systemic illness.&#xD;
&#xD;
         10. Allergy, hypersensitivity, or thrombocytopenia from heparin, Recombinant tissue&#xD;
             plasminogen activator (rtPA), dexamethasone sodium phosphate or iodinated contrast,&#xD;
             except for mild-moderate contrast allergies for which steroid pre-medication can be&#xD;
             used.&#xD;
&#xD;
         11. History of, or active heparin-induced thrombocytopenia (HIT).&#xD;
&#xD;
         12. Haemoglobin &lt; 9.0 mg/dl, INR &gt; 1.6 before starting anticoagulation, or platelets &lt;&#xD;
             100,000/ml. Moderate renal impairment in diabetic patients (estimated glomerular&#xD;
             filtration rate &lt; 60 ml/min) or severe renal impairment in non-diabetic patients&#xD;
             (estimated glomerular filtration rate &lt; 30 ml/min).&#xD;
&#xD;
         13. Active bleeding, recent (&lt; 3 mo) GI bleeding, severe liver dysfunction, bleeding&#xD;
             diathesis.&#xD;
&#xD;
         14. Recent (&lt; 3 mo) internal eye surgery or haemorrhagic retinopathy; recent (&lt; 10 days)&#xD;
             major surgery, cataract surgery, trauma, cardiopulmonary resuscitation, obstetrical&#xD;
             delivery, or other invasive procedure.&#xD;
&#xD;
         15. History of hemorrhagic stroke or intracranial/intraspinal bleed, tumor, vascular&#xD;
             malformation, aneurysm.&#xD;
&#xD;
         16. Active cancer with a life expectancy of &lt;2 years.&#xD;
&#xD;
         17. Severe hypertension on repeated readings (systolic blood pressure &gt; 180 mmHg or&#xD;
             diastolic blood pressure &gt; 105 mmHg). This can be treated, and blood pressure must be&#xD;
             stable before venous access is obtained (systolic blood pressure &lt;140 mmHg).&#xD;
&#xD;
         18. Pregnant or breastfeeding.&#xD;
&#xD;
         19. Life expectancy &lt; 2 years.&#xD;
&#xD;
         20. Thrombus of the inferior vena cava (IVC) extending at least one centimeter above the&#xD;
             common iliac confluence.&#xD;
&#xD;
         21. Inability to obtain venous access.&#xD;
&#xD;
         22. Inability to recanalize the target vein segment(s).&#xD;
&#xD;
         23. History of ipsilateral venous stent.&#xD;
&#xD;
         24. DVT length to be targeted for perivascular drug therapy exceeds 50 cm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kirk Seward, PhD</last_name>
    <phone>510-614-4550</phone>
    <email>kseward@mercatormed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

